This stock is no longer traded. It was delisted on September 15, 2026. Prices stop on that date; discussion is still counted.
Generated by AI
Pasithea Therapeutics Corp. Warrant represents a unique financial instrument associated with Pasithea Therapeutics, a company engaged in advancing scientific research and development in the healthcare and pharmaceutical sectors. Warrants provide holders the right, but not the obligation, to purchase shares of Pasithea Therapeutics at a predetermined price before the expiration date. This asset allows investors to potentially leverage their exposure to the company's future growth prospects without initially committing large capital outlays required for buying stock outright. The key feature of this warrant is its potential to provide amplified returns if Pasithea Therapeutics' stock appreciates, attracting investors interested in innovative treatments for mental health therapies. Operating in the dynamic biopharmaceutical industry, the issuance of such warrants helps Pasithea Therapeutics raise capital while offering investors a speculative tool to participate in the volatile biotech market. Warrants like these play a vital role in a company's capital strategy, providing access to funds that support ongoing research and development efforts.
Website1111 Lincoln Road
Miami Beach, FL, 33139
United States
The latest articles about KTTAW.
Detailed price information for Pasithea Therapeutics Corp (KTTA-Q) from The Globe and Mail including charting and trades.
Summary of Feb 11's posts. Generated by AI.
No summary yet.
No summary yet.
No summary yet.
No summary yet.
Investors talking about KTTAW also mention these. Each card shows that asset’s own numbers for the past 24 hours.